Jessica N. Abraham | Designer. Writer. Publicist.

19+ Years of Expertise in Digital Marketing, Social Branding and Public Relations.

  • Home
  • Contact
  • About
  • Home
  • Contact
  • About

No Widgets found in the Sidebar Alt!

  • Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life.
    Benzinga,  Biotechnology,  Health,  Nature,  Regenerative Medicine

    Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    June 15, 2022 /

    Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market  is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …

    read more
    Jessica N. Abraham Comments Off on Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It

    You May Also Like

    Renewable Energy, Solar Panels, Clean Energy 2030, Benzinga, SinglePoint, Jessica Abraham

    An Empire For Solar Discovery And Education In The Making? SinglePoint Reports Building Out Network For Clean Air And Green Energy Efficiency

    March 17, 2022
    Cell Transplant, Eye Transplant, Cellular Regeneration, Regeneration Therapy,

    Lineage, Pioneering a New Branch of Medicine — OpRegen Continues to Show Promising Results in Dry AMD with Geographic Atrophy

    October 21, 2021
    Battery management systems, battery technologies, battery safety, kulr, benzinga

    NASA-Approved Technologies Essential to Creating Cooler, Lighter and Safer Batteries for EV, Aeronautics and Smart Device Technologies

    July 8, 2021
  • What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
    Business,  Benzinga,  Biotechnology,  Finance,  Health

    What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

    September 8, 2021 /

    Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest Life Sciences, Inc. Last week, the company provided an update on its integration of ImQuest and its plans going forward.  According to Statera, preclinical testing is underway in the screening of second-generation immune therapies using the ImQuest platform for the rapid and accurate assessment of various diseases and how the overall makeup and composition of these diseases interact. The company will look more closely…

    read more
    Jessica N. Abraham Comments Off on What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?

    You May Also Like

    parcelpost parcelpal Last week, ParcelPal Logistics Inc. (OTCQB: PTNYF), a US and Canadian-based organization specializing in last-mile delivery services and logistics-related solutions, announced that it would acquire another well-known and currently unnamed U.S. delivery service, citing a “letter of intent” between both parties after almost 8 months of successful, rapidly-growing co-operations at the company’s west coast facility.

    US and Canadian Delivery Service to Acquire Another U.S. Delivery Services Company, Executes New Canadian Service Agreement in the Same Week

    December 2, 2021
    Mobile Apps, Digital Pivot, Blobal Med Company, Healthcare, HIT, Healthcare Technology, Real-Time Communications, Habit Tracker, Health, Healthcare IT, iOS, New Year's Resolution, ORCAS, Productivity, Technology, Tech News, Technology News, The Good Habit App, Michael Mulvihill, MindSet, Weight Loss,

    Keep Your New Year’s Resolution with the Good Habit App

    December 8, 2015
    Shorty Produkshins, Brand Social, Jessica Abraham, Jessica N Abraham, Brand Social, Internet Marketing, Internet Marketing Orlando, Internet Marketing Warren, Atlanta, Warren Ohio, Punxsutawney, Punxsy, Washington DC, Nashville, Dallas, Memphis, Baltimore, Orlando, Public Relations, Media Design, Content Development, Design Strategy, Social Branding, Social Media, Toronto, Philadelphia, Now Hiring, Work at Home, WAH, Nigeria, Los Angeles, Las Vegas,

    Lack of Social: So Many Businesses are STILL Doing it Wrong!

    February 27, 2013
  • Business
  • Technology
  • Career Development
  • Education
  • Entertainment
  • Fashion
  • Relationships
  • Tips
  • Travel
Ashe Theme by WP Royal.